Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers

The Trump administration is reportedly planning a pilot program to allow voluntary Medicare Part D and state Medicaid coverage for costly GLP-1 obesity drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, with implementation slated for 2026-2027. This potential policy shift, if enacted, represents a significant positive for pharmaceutical companies by addressing a major barrier to patient access and could substantially boost sales volumes for these blockbuster drugs. While the government is expected to impose coverage parameters and negotiate pricing below current list prices, this development signals a notable shift in industry sentiment regarding broader reimbursement for obesity treatments.

Analysis

A reported pilot program under the Trump administration to allow voluntary Medicare and Medicaid coverage for GLP-1 obesity drugs represents a significant potential catalyst for key manufacturers Eli Lilly and Novo Nordisk. This plan, if implemented, would directly address the primary growth constraint for drugs like Zepbound and Wegovy: limited insurance coverage for treatments costing approximately $1,000 per month. While Mizuho analysis suggests the government will likely negotiate prices below current list levels and impose coverage restrictions based on factors like BMI and comorbidities, the expansion of access could drive substantial volume growth. The proposed timeline, starting in April 2026 for Medicaid and January 2027 for Medicare, provides a medium-term outlook for this market expansion. This development is a notable shift, given a previous proposal was dropped due to cost concerns of up to $35 billion over a decade, and is now viewed as a positive for overall industry sentiment. This also benefits pipeline competitors such as Amgen, AstraZeneca, and Pfizer, who stand to gain from a more favorable reimbursement landscape for obesity treatments.

Key Decisions for Investors

• Investors with exposure to Eli Lilly (LLY) and Novo Nordisk (NVO) should view this potential policy shift as a significant de-risking event that reinforces the long-term bullish thesis for the obesity drug market, while monitoring for official confirmation of the program.
• It is prudent to model future revenue scenarios with lower net prices for the Medicare and Medicaid segments, as the government is expected to negotiate significant discounts from the current list prices in exchange for broad access.
• The 2026-2027 implementation timeline indicates this is a medium-term catalyst, meaning near-term stock performance will be driven by sentiment while fundamental financial impact is still several years away.
• Consider the positive spillover effect for companies with obesity treatments in development, like Amgen (AMGN) and Pfizer (PFE), as a clearer federal reimbursement path could increase the probability of success for their future products.